In their pioneering disease modeling work, Moretti et al. notably observed action potential prolongations following isoprenaline treatment specifically in LQT1 cells, which confirms our FPD data and extends its relevance from JLNS to LQT1 in general (Moretti et al., 2010). The gene discussed is KCNE1; the disease is long QT syndrome 1.